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The RAS/RAF/MAPK pathway likely mediates critical cell proliferation and survival signals in melanoma. BRAF
mutations have been found in a high percentage of melanoma cell lines and metastases; however, only a few
studies with a limited number of specimens have focused on primary melanomas. We examined BRAF exon 15
mutational status in 37 primary invasive melanomas of varying thicknesses, which had undergone a standardized
pathology review. BRAF mutational status was determined using direct manual sequencing of PCR products,
followed by resequencing separately ampliﬁed DNA aliquots to conﬁrm each mutation. BRAF exon 15 mutations
were found in 17 of 37 (46%) primary melanomas. Tumor-speciﬁc tandem mutations, encoding either V599K, V599R,
or V599E, were found in 5 of 17 (29%) melanomas with BRAF exon 15 mutations. Cloning of BRAF double base-pair
substitutions conﬁrmed that both base changes were on the same allele and can result in a positive charge at
codon 599. BRAF mutations, including tandem mutations, were frequently found in both thin and thick primary
melanomas, implying that these mutations can occur early in the progression of melanoma. The ﬁnding of tandem
mutations in thin melanomas makes it more likely that they arise as a simultaneous rather than sequential event.
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Melanoma, which frequently metastasizes and generally is
resistant to medical treatment, more than tripled in
incidence among Caucasians between 1980 and 2003,
bringing the estimated number of new invasive melanomas
to 54,200 with 7600 deaths for the year 2003 in the United
States (Jemal et al, 2003). Due to the increasing burden of
this potentially lethal disease, methods of prevention, early
diagnosis, and treatment of melanoma are expected to be
of increasing importance. Improved understanding of the
molecular alterations present in primary cutaneous mela-
noma and the point in melanoma progression that they
occur should facilitate advances in these areas.
BRAF encodes a serine/threonine kinase downstream of
RAS in the RAS/RAF/MAPK pathway that is involved in
transduction of mitogenic signals from membrane receptors
to the nucleus. Through a systematic genomewide screen
for mutations in signaling pathways where at least one gene
was mutated in human cancer, somatic mutations in the
BRAF gene in melanomas were found (Davies et al, 2002).
BRAF mutations have been found in approximately
40%–80% of melanomas and nevi (Brose et al, 2002;
Davies et al, 2002; Dong et al, 2003; Gorden et al, 2003;
Kumar et al, 2003; Pollock et al, 2003; Uribe et al, 2003).
One group, however, reported finding BRAF exon 15
mutations in only two of ten (10%) of radial growth phase
(RGP) melanomas, whereas they found BRAF mutations in
five of eight (75%) of vertical growth phase (VGP)
melanomas (Dong et al, 2003). RGP melanomas can either
be in situ or have single cells or small clusters of tumor cells
without mitoses in the papillary dermis; whereas VGP mela-
nomas would show the opposite, such as cellular clusters in
the dermis larger than the largest intraepidermal nest and/or
mitoses in the dermal melanoma cells. These authors
conclude that BRAF mutations are involved in progression
rather than initiation of melanoma (Dong et al, 2003).
The most common BRAF mutation, accounting for 92%
of BRAF mutations in the melanoma samples tested by
Davies et al (2002), is that of the 1796T ! A transversion in
exon 15, which results in a V599E substitution. The BRAF
V599E variant was demonstrated to transform NIH3T3 cells
138 times more efficiently than wild-type (wt) and to have
10.7-fold increased basal kinase activity (Davies et al, 2002).
Importantly, using RNA interference experiments, it has
been shown that BRAF V599E, when present, is necessary
for melanoma cell viability and transformation (Hingorani
et al, 2003). Thus, compounds that inhibit activated BRAF
are likely to be efficacious in the treatment of melanoma.
The BRAF 599 site, which is in the BRAF activation
segment, is near T598 and S601, which require phosphor-
ylation for maximal BRAF kinase activation (Zhang and
Guan, 2000). As has been demonstrated for other protein
kinases, Davies et al (2002) have suggested that the intro-
duction of negative charges in the activation segment may
mimic activating phosphorylations, yielding activated kinase.
Abbreviations: LMM, lentigo maligna melanoma; NM, nodular
melanoma; RGP, radial growth phase; SSM, superficial spreading
melanoma; VGP, vertical growth phase; wt, wild-type
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We previously reported BRAF exon 15 double mutations
at codon 599 in three primary invasive melanomas.1 In
addition, BRAF 599 double mutations have been reported in
two other primary melanomas, a few metastatic melano-
mas, a melanoma cell line, and a congenital nevus (Davies
et al, 2002; Pollock et al, 2003; Dong et al, 2003; Gorden
et al, 2003; Kumar et al, 2003; Uribe et al, 2003). Gorden et
al (2003) also reported a tandem base-pair substitution,
GG1402/1403TC, encoding a BRAF G468S amino acid
change in a metastasis. No detailed clinical-pathologic data
has previously been reported for tandem mutations in
primary melanomas.
In this study, we examined a series of 19 hospital-based
and 18 population-based primary cutaneous invasive hu-
man melanomas, including thin (p0.75 mm Breslow depth)
and thick melanomas, which had undergone a standardized
pathology review. BRAF exon 15 mutational status was
determined using manual sequencing, followed by rese-
quencing a separately amplified DNA aliquot to confirm the
mutation. Furthermore, double BRAF mutations that were
found were cloned to determine if they occurred together
on the same allele or were separate point mutations on
different alleles.
Results and Discussion
Our study finds BRAF mutations to be frequent in primary
melanomas, including both thin and thick melanomas. Of
the 37 primary melanomas evaluated, 17 (46%) were found
to harbor BRAF exon 15 alterations, all resulting in amino
acid changes, as shown in Table I. A high prevalence of
BRAF exon 15 mutations was found in both the hospital-
based (37%) and the population-based (56%) series. The
melanoma depths differ between these two groups, with the
hospital-based samples being of substantially thicker mean
Breslow depth than the population-based samples, con-
sistent with The University of North Carolina Hospitals being
a tertiary referral center.
Of note, seven of ten (70%) of the thin melanomas
(p0.75 mm) had BRAF exon 15 mutations. Although two of
these had histologically contiguous nevi that may not have
been entirely separated out from the melanoma in the
dissection process, five had no associated nevi. In those
cases, analysis would represent the mutational status of the
melanoma alone. Our study cannot be directly compared
with that of Dong et al (2003), as they included melanoma
in situ as part of their RGP melanoma group and did not
report Breslow depth on their VGP group; however, our
study finds that BRAF mutation is frequent once melano-
mas have early invasion (p0.75 mm Breslow depth).
Our data indicates that tandem mutations comprise a
substantial percentage (29%) of the BRAF exon 15
mutations found in primary melanomas. Tandem mutations
were similarly found in both the population-based and the
hospital-based series, with five of 17 (29%) of the samples
with BRAF exon 15 mutations containing tandem mutations.
A 1795–96GT ! AG change resulting in V599R, two 1795–
96GT ! AA alterations resulting in V599K, two 1796–
97TG ! AA changes resulting in V599E, and a novel
1779T ! A alteration resulting in D593E were discovered.
Figure 1 shows sequencing results of BRAF exon 15 in two
of the primary melanoma samples that displayed double
mutations, the positive control cell line, Colo 205, which
carries the V599E mutation (Davies et al, 2002), and a
negative control from peripheral blood.
We confirmed by cloning that these double mutations are
in tandem positions on the same allele and, therefore, can
result in positively charged amino acid substitutions. One of
each of the melanomas carrying V599K, V599R, and V599E
tandem mutations was cloned and sequenced and the
double base changes in each case were shown to occur on
the same allele, rather than being two separate point
mutations on different alleles or resulting from a hetero-
geneous population of cells with different mutations.
Automated sequencing analyses of cloned exon 15 PCR
fragments from melanomas with a V599K and V599R
tandem mutations are shown in Fig 2. The cloning confirms
the amino acid sequence of the BRAF tandem mutations
and verifies that these mutations can result in positively
charged substitutions (V599R and V599K) in some samples
and negatively charged amino acid substitutions (V599E) in
others. This is in agreement with Gorden et al (2003) who
cloned and sequenced a GT/AG BRAF V599R double
mutation from a melanoma metastasis and found both
base-pair substitutions to be on the same allele.
Previous reports have suggested that oncogenic muta-
tions in BRAF introducing negative charges in the activation
segment of exon 15 may be mimicking activating phos-
phorylations (Davies et al, 2002). Because the tandem
mutations found can result in lysine and arginine substitu-
tions in the activation segment, as confirmed by cloning, our
results suggest that mutations creating positive charges in
this segment of BRAF exon 15 may stabilize active
conformations of the kinase, a finding that has mechanistic
implications. In support of this, Dong et al (2003) found that
the BRAF V599K mutant has transforming activity in NIH3T3
cells and can produce rapidly growing tumors in SCID mice
(Dong et al, 2003).
We have shown that the tandem mutations are tumor
specific. Areas of normal-appearing skin adjacent to
melanomas from the hospital-based series carrying BRAF
tandem mutations resulting in V599K, V599R, and V599E
alterations were also isolated and analyzed for mutations.
No mutations were found in areas of normal skin from these
samples, consistent with the BRAF tandem gene alterations
being tumor-specific somatic mutations rather than germ-
line polymorphisms. Germline DNA or normal tissue from
cases with BRAF melanoma mutations have been found to
be negative for the BRAF alteration in other studies (Davies
et al, 2002; Yuen et al, 2002; Gorden et al, 2003; Uribe et al,
2003).
Notably, tandem mutations were found in primary
melanomas as thin as 0.38 and 0.40 mm Breslow thickness,
Clark level II and in a melanoma that was still in RGP. These
findings provide evidence that these tandem mutations
occur early in the progression of melanoma, making it more
1Thomas NE, Alexander A, Edmiston S, Parrish E, Millikan RC,
Groben P, Ollila D, Conway K: Tandem BRAF mutations in primary
human melanomas. Proc Am Assoc Cancer Res (2nd ed.) 44:1357,
2003 (abstr).
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Table I. BRAF exon 15 mutations in primary cutaneous invasive melanomas and their associated clinicopathologic features
Sex Age (y) Nucleotide Amino acid Histologic subtype Breslow depth (mm) Clark level
Hospital-based series
M 81 GT1795–96AG V599R SSM 3.65 IV
M 71 GT1795–96AA V599K SSM 3.50 IV
M 47 TG1796–97AA V599E UNCL 10.00 V
F 33 T1796A V599E SSM 0.82 III
M 38 T1796A V599E SSM 5.70 IV
M 31 T1796A V599E SSM 0.75 IV
M 68 T1779A D593E NM 2.60 IV
F 89 wt – SSM 4.60 V
F 76 wt – UNCL 1.30 III
F 26 wt – NM 1.00 III
F 43 wt – SSM 0.59 IIa
F 35 wt – SSMb 1.30 IV
F 78 wt – SSM 4.60 V
M 82 wt – LMM 1.78 IV
M 83 wt – LMM 3.65 IV
M 31 wt – NM 1.53 IV
F 70 wt – SSM 0.93 IV
F 76 wt – SSM 1.25 III
M 58 wt – LMM 13.65 V
Population-based series
F 60 GT1795–96AA V599K SSM 0.40 IIa
F 32 TG1796–97AA V599E SSMc 0.38 II
F 32 T1796A V599E SSM 0.85 IV
M 31 T1796A V599E SSMd 1.00 III
M 56 T1796A V599E SSM 0.70 III
F 34 T1796A V599E SSM 0.52 IV
F 59 T1796A V599E SSM 1.20 IV
F 45 T1796A V599E SSM 0.99 IV
M 25 T1796A V599E SSM 0.44 III
M 52 T1796A V599E SSM 0.58 III
F 74 wt – SSM 1.60 IV
F 51 wt – SSM 2.10 IV
F 68 wt – NM 3.40 IV
F 78 wt – NM 2.50 IV
M 58 wt – SSM 0.70 IV
F 27 wt – SSM 2.20 IV
F 38 wt – SSM 0.55 II
F 73 wt – SSM 0.88 IV
wt, wild-type BRAF allele detected; SSM, superficial spreading melanoma; UNCL, unclassified melanoma; NM, nodular melanoma; LMM, lentigo
maligna melanoma.
aThese two melanomas were in RGP¼ radial growth phase; all others had a VGP¼ vertical growth phase.
bHistologically contiguous with a dysplastic nevus.
cHistologically contiguous with a common acquired nevus.
dHistologically contiguous with a congenital nevus.
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likely that they occur as a simultaneous rather than
sequential event.
In the literature, tandem base mutations that are not
opposite bi-pyrimidines appear to be rare in human tumors;
a literature search did not reveal any such reported
mutations other than BRAF tandem mutations. Besides
being found in melanoma, tandem BRAF V599D mutations
have also been reported in two of 15 cholangiocarcinomas
with BRAF exon 15 mutations, but none have been reported
in other tumor types (Tannapfel et al, 2003).
Lee et al (2002) suggest that tandem mutations could
occur through several possible mechanisms, including: (i) a
single-base lesion promoting a double misincorporation
event during DNA replication; (ii) cross-linked adjacent DNA
bases; or (iii) adjacent base lesions (tandem lesions)
promoting misincorporation opposite to the two lesions. In
addition, tandem mutations have been associated with
deficient nucleotide excision repair (Lee et al, 2002). It is
possible that tandem mutations may arise due to a
deficiency in nucleotide excision repair (Lee et al, 2002) or
a lack of fidelity in this process. The majority of the BRAF
mutations reported are at codon 599 (GTG) of the sequence
50-GTG AAA-30. The adjacent di-pyrimidines on the non-
coding strand may form dimers in response to ultraviolet
damage and mutations at the codon 599 may occur during
DNA repair. Mutations near but not directly opposite bi-
pyrimidines have been found in response to ultraviolet light
in Escherichia coli (Oller et al, 1992).
Additionally in our series, a novel BRAF D593E mutation
was found in a nodular melanoma (NM) with 2.6 mm
Breslow thickness. The wt aspartic acid residue at this
position is in the DFG (AspPheGly) sequence at the start of
the activation segment and is highly conserved in all protein
kinases. This aspartic acid residue is involved in binding an
ATP chelating metal and has been identified as the catalytic
residue in phosphorylase kinase due to its proximity to
Figure 1
Sequencing analysis of BRAF codon 599 mutations in primary
melanomas. Melanoma 1 exhibits a double mutation in codon 599 of
GTG to AGG, whereas melanoma 2 exhibits a different double mutation
in codon 599 of GTG to AAG. The negative control is normal DNA from
peripheral blood. The positive control Colo205 displays a single base
change of GTG to GAG in codon 599. Arrows indicate mutant bases
identified by sequencing.
Figure 2
Cloning and automated sequence
analysis of BRAF codon 599 double
mutants from primary melanomas.
After cloning the PCR fragments of
mutated BRAF, the altered bases in the
melanomas with double mutations were
found to be on the same DNA strand. (A)
Wild-type GTG sequence at codon 599
is shown. (B) Melanoma 1 can be seen
to have a GTG to AGG alteration at
codon 599. (C) Melanoma 2 can be seen
to have a GTG to AAG alterations at
codon 599.
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substrate in the catalytic site (Johnson et al, 1998).
Substitution of alanine for aspartic acid at position 593 in
BRAF eliminates kinase activity (Davies et al, 2002). BRAF
D593V and D593G substitutions have been found in
colorectal cancers (Yuen et al, 2002; Wang et al, 2003).
BRAF 599 mutations in melanomas were analyzed for
potential associations with clinicopathologic features. The
BRAF D593E mutant was not included in the analysis as
mutations at position 593 can eliminate kinase activity and,
thus, it is unclear whether or not BRAF D593E is an
activating mutation. Our data show a statistically significant
association of BRAF 599 mutation in primary invasive
melanomas with superficial spreading melanoma (SSM)
(p¼ 0.03) versus other histologic subtypes. The frequency
of BRAF 599 mutation was found to be significantly greater
in SSM melanomas (15 of 27; 56%) than in melanomas of
other subtypes (one of eight; 13%). Specifically, in our
series, all melanomas with BRAF 599 mutations were SSM,
with the exception of one unclassifiable melanoma. No
statistically significant correlations were detected between
BRAF 599 mutational status and age, anatomic site, Clark
level, solar elastosis, and nevus association in these
melanomas (data not shown). There was a borderline
negative association between BRAF mutational status and
increasing Breslow depth (p¼ 0.05). Our data show a
possible but not statistically significant association of BRAF
mutation in primary melanomas with the male gender
(p¼ 0.09). This is of note as Uribe et al (2003) have found
an association of BRAF mutational positivity in atypical nevi
and melanomas with the male gender. Further examination
of a larger population-based series of melanomas will allow
a more thorough evaluation of frequency of BRAF mutation,
including the subset of tandem mutations and potential
associations with clinicopathologic variables.
Intermittent, recreational type sun exposure has been
linked to most subtypes of melanoma, except for lentigo
maligna melanoma (LMM), which is associated with chronic
or occupational exposure (Elwood and Jospon, 1997;
Armstrong and Kricker, 2001). Both UVB and UVA have
been implicated as possible etiologic agents, and oxidative
damage has also been suggested as a possible source of
DNA damage in melanoma. Whether the type of tandem
mutation reported in this study represents a ‘‘fingerprint’’ for
an etiologic process remains to be elucidated. Further study
of these tandem mutations in population-based melanoma
samples along with epidemiologic data may ultimately shed
light on the processes involved in the development of
melanoma.
Materials and Methods
Sample selection and pathology review The samples consisted
of 37 primary invasive cutaneous human melanomas. Nineteen of
these were archived primary human melanomas selected at
random from a series of cases treated at UNC Hospitals after
1995, which had Breslow thicknesses from 0.59 to 13.65 mm
(mean 3.3 mm). An additional 18 melanoma samples came from a
larger population-based series in North Carolina in the year 2000,
which had Breslow thicknesses from 0.38 to 3.40 mm (mean 1.2
mm). These tumors were selected from this population-based
sample set based on sequential date of receipt of the tissue blocks
that fulfilled the study criteria of primary cutaneous invasive
melanoma in the year 2000 in designated counties of North
Carolina and size of tumor dense enough so as not to require laser
capture microdissection. Of 24 sequential cases of melanoma, six
cases (all p0.6 mm) were put aside for laser capture microscopy,
and the other 18 were included in this study. This population-based
study is part of an international melanoma study. Both studies were
approved by the Institutional Review Board of the University of
North Carolina. Review of the histopathology was performed by
one dermatopathologist (P. G.) who was blinded to the mutational
status of the cases. An unclassified melanoma is one that could not
be classified as SSM, NM, LMM, or acral lentiginous.
Preparation of DNA from melanomas After sectioning of the
paraffin-embedded tumor blocks obtained from the cases, the
areas of melanoma were identified by a dermatopathologist (P. G.)
and dissected from the surrounding tissue under  2 magnifica-
tion. Normal appearing skin was also dissected off the slides and
isolated separately for the hospital-based samples carrying
tandem BRAF mutations. Tissues were incubated for 4 h at 561C
in lysis solution containing 1 mg per mL proteinase K, 1% Triton-X,
50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 0.001% gelatin, then
were incubated overnight at 371C. Proteinase K was then
inactivated by heating to 951C for 10 min. The lysates were
centrifuged for 10 min at 13,000 g to remove debris and subjected
to molecular assays for BRAF exon 15 mutations as described
below.
Polymerase chain reaction BRAF exon 15 was amplified by PCR
in a 50 mL reaction volume containing 1–5 mL of tumor DNA lysate,
400 nmol of each primer (forward: 50-TCATAATGCTTGCTCTGA-
TAGGA, primer 1; reverse: 50-GGCCAAAAATTTAATCAGTGGA,
primer 2) (Davies et al, 2002), 1.5 U of AmpliTaq Gold DNA
polymerase (Applied Biosystems, Foster City, California), 1  PCR
buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2,
0.001% gelatin), and 125 mM each dNTP. PCR was carried out for
one cycle of 951C for 4 min., followed by 35 cycles of 951C for 30 s,
571C for 1 min, and 721C for 1 min, and a final extension of 721C for
10 min for one cycle. The quantity of each PCR product obtained
was analyzed on 10% polyacrylamide gels.
Sequencing The PCR products were purified by electrophoresis
in 10% polyacrylamide gel. Bands were isolated from the gels and
incubated overnight in 500 mL TE, then were purified using a
Promega Wizard PCR purification system (Promega, Madison,
Wisconsin). Two asymmetric PCR reactions were prepared to
generate two single-stranded DNA products in both the forward
and reverse directions. The first asymmetric PCR reaction
consisted of 300 nM of primer 1 and 6 nM of primer 2, whereas
the second reaction contains 6 nM primer 1 and 300 nM primer 2.
All other reaction conditions were the same as described for first
round PCR. The amplified single-stranded product was prepared
for sequencing by filtration through Centricon 100 spin filters
(Amicon, Houston, Texas). The product was sequenced with the
Sequenase 2.0 dideoxy-termination method using 35S-dATP to
visualize the bands. All mutations were confirmed by sequencing in
a separately amplified aliquot of DNA to rule out artifactual
mutations.
Cloning of BRAF exon 15 mutants BRAF exon 15 was cloned
into the pDrive vector (Qiagen, Valencia, California), and plasmid
DNA minipreps were prepared from each clone using Qiaprep spin
minipreps (Qiagen). DNA was sequenced at the UNC-CH Auto-
mated DNA Sequencing Facility on a 3100 Genetic Analyzer
(Applied Biosystems).The sequencing reaction was done using the
ABI PRISMTM BigDyeTM Terminator Cycle Sequencing Ready
Reaction Kit with AmpliTaq DNA Polymerase, FS (Applied
Biosystems).
Statistical analysis p-Values were derived from the Fisher’s exact
test. All statistical analyses were performed using SAS system
version 8.02 (Cary, North Carolina).
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